Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
11
04
2022
accepted:
19
07
2022
pubmed:
16
2
2023
medline:
21
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Vedolizumab (VDZ) is an anti-α 4 β 7 integrin monoclonal antibody approved for inflammatory bowel disease treatment. VDZ serum and antidrug antibody (ADA) concentrations may be used for treatment optimization. In this article, the results of 5 commercial assays (Grifols, Immundiagnostik, Progenika, Sanquin, and Theradiag) measuring VDZ concentration and ADA were compared with those of the reference assays used in VDZ clinical studies. Our findings will assist clinicians in interpreting commercial assay results in the context of VDZ clinical trial data. VDZ-treated patient samples were used to evaluate the agreement between commercial assays and the reference VDZ serum concentration assay, based on linear regression, Bland-Altman, and qualitative agreement analyses. VDZ ADAs were detected using qualitative assays. Specificity, selectivity, accuracy, and precision were assessed using serum samples from healthy donors or patients with IBD (VDZ serum concentration <0.5 mcg/mL) spiked with VDZ, with/without other biologics (identical sample sets per assay). All assays were specific and selective for VDZ. Overall, the commercial assay results for VDZ-spiked samples correlated well with those of the reference serum concentration assay (R 2 ≥ 0.98). Compared with the Immundiagnostik and Theradiag assays, the Grifols, Sanquin, and Progenika assays had the best reference assay agreement (based on regression analysis, Bland-Altman plots, and qualitative agreement [Cohen's kappa ≥0.92]). All immunogenicity assays detected VDZ ADAs; only the reference assay detected VDZ ADAs in the presence of 15 mcg/mL VDZ, advising caution with commercial ADA assays if VDZ is present. All 5 commercial assays are suitable for VDZ therapeutic monitoring and ADA testing. However, the absolute values from the reference assays and the different commercial assays were not comparable, indicating that the same assay must be used for repeated monitoring of VDZ serum concentrations.
Sections du résumé
BACKGROUND
Vedolizumab (VDZ) is an anti-α 4 β 7 integrin monoclonal antibody approved for inflammatory bowel disease treatment. VDZ serum and antidrug antibody (ADA) concentrations may be used for treatment optimization. In this article, the results of 5 commercial assays (Grifols, Immundiagnostik, Progenika, Sanquin, and Theradiag) measuring VDZ concentration and ADA were compared with those of the reference assays used in VDZ clinical studies. Our findings will assist clinicians in interpreting commercial assay results in the context of VDZ clinical trial data.
METHODS
VDZ-treated patient samples were used to evaluate the agreement between commercial assays and the reference VDZ serum concentration assay, based on linear regression, Bland-Altman, and qualitative agreement analyses. VDZ ADAs were detected using qualitative assays. Specificity, selectivity, accuracy, and precision were assessed using serum samples from healthy donors or patients with IBD (VDZ serum concentration <0.5 mcg/mL) spiked with VDZ, with/without other biologics (identical sample sets per assay).
RESULTS
All assays were specific and selective for VDZ. Overall, the commercial assay results for VDZ-spiked samples correlated well with those of the reference serum concentration assay (R 2 ≥ 0.98). Compared with the Immundiagnostik and Theradiag assays, the Grifols, Sanquin, and Progenika assays had the best reference assay agreement (based on regression analysis, Bland-Altman plots, and qualitative agreement [Cohen's kappa ≥0.92]). All immunogenicity assays detected VDZ ADAs; only the reference assay detected VDZ ADAs in the presence of 15 mcg/mL VDZ, advising caution with commercial ADA assays if VDZ is present.
CONCLUSIONS
All 5 commercial assays are suitable for VDZ therapeutic monitoring and ADA testing. However, the absolute values from the reference assays and the different commercial assays were not comparable, indicating that the same assay must be used for repeated monitoring of VDZ serum concentrations.
Identifiants
pubmed: 36788448
doi: 10.1097/FTD.0000000000001068
pii: 00007691-202304000-00015
pmc: PMC10013162
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
Tumor Necrosis Factor-alpha
0
vedolizumab
9RV78Q2002
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-244Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Références
Strik AS, Wang YMC, Ruff LE, et al. Individualized dosing of therapeutic monoclonal antibodies—a changing treatment paradigm? AAPS J. 2018;20:99.
Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655–1668.e3.
Guiotto C, Daperno M, Frigerio F, et al. Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Dig Liver Dis. 2016;48:138–143.
Marini JC, Sendecki J, Cornillie F, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade. AAPS J. 2017;19:161–171.
Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol. 2014;109:1055–1064.
Vande Casteele N. Assays for measurement of TNF antagonists in practice. Frontline Gastroenterol. 2017;8:236–242.
Vande Casteele N, Buurman DJ, Sturkenboom MGG, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765–771.
Aguas Peris M, Bosó V, Navarro B, et al. Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice. Inflamm Bowel Dis. 2017;23:1454–1460.
Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628–1640.
Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:80–84. e82.
Lee MWM, Connor S, Ng W, Toong CML. Comparison of infliximab drug measurement across three commercially available ELISA kits. Pathology. 2016;48:608–612.
Sam MJ, Connor SJ, Ng WWS, Toong CML. Comparative evaluation of 4 commercially available ELISA kits for measuring adalimumab and anti-adalimumab antibodies. Ther Drug Monit. 2020;42:821–828.
Entyvio (Vedolizumab) Prescribing Information. Takeda Pharmaceuticals America, Inc; 2022; Deerfield, IL, USA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125476Orig1s046lbl.pdf . Accessed July 29, 2022.
Entyvio INN-Vedolizumab Summary of Product Characteristics. Takeda Pharma A/S. Amsterdam, The Netherlands: European Medicines Agency; 2022; Taastrup, Denmark. https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf . Accessed July 29, 2022.
Nassar IO, Cheesbrough J, Quraishi MN, Sharma N. Proposed pathway for therapeutic drug monitoring and dose escalation of vedolizumab. Frontline Gastroenterol. 2022;13:430–435.
Schulze H, Esters P, Hartmann F, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol. 2018;53:670–676.
Vande Casteele N, Sandborn WJ, Feagan BG, et al. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022;56:463–476.
Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158:562–572.e12.
Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for crohn's disease. N Engl J Med. 2013;369:711–721.
Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015;42:188–202.
Wyant T, Yang L, Rosario M. Comparison of the ELISA and ECL assay for vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 GEMINI trials. AAPS J. 2020;23:3.
Freeth D, Sandall J, Allan T, et al. A methodological study to compare survey-based and observation-based evaluations of organisational and safety cultures and then compare both approaches with markers of the quality of care. Health Technol Assess. 2012;16:iii–iv, 1-184.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327:307–310.
Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015;25:141–151.
Pérez I, Fernández L, Sánchez-Ramón S, et al. Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels. Therap Adv Gastroenterol. 2018;11:1–10.
Fleiss JL, Levin B, Paik MC. The measurement of interrater agreement. In: Shewart WA, Wilks SS, eds Statistical Methods for Rates and Proportions. Hoboken, NJ: John Wiley & Sons, Inc.; 2003:598–626.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
Vande Casteele N, Sandborn W, Feagen BG, et al. Real-world exposure-response relationship of vedolizumab in inflammatory bowel disease: a pooled multicentre observational cohort analysis of clinical and modeled pharmacological data. United Eur Gastroenterol J. 2020;8:403.